PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.\', \'Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui, 230001, China.\', \'The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.\', \'Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China. ustcwhm@ustc.edu.cn.\', \'Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui, 230001, China. ustcwhm@ustc.edu.cn.\', \'The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. ustcwhm@ustc.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s12967-020-02339-3
?:doi
?:hasPublicationType
?:journal
  • Journal of translational medicine
is ?:pmid of
?:pmid
?:pmid
  • 32290839
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.565
?:rankingScore_hIndex
  • 81
is ?:relation_isRelatedTo_publication of
?:title
  • Why tocilizumab could be an effective treatment for severe COVID-19?
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all